Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc (CNTA) priced its initial public offering on Jun 1, 2021 at $20.00 per share, raising $330M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.75B. Morgan Stanley was lead-left underwriter, joined by Goldman Sachs, Jefferies and Evercore ISI. Goodwin Procter advised the company and Cooley advised the underwriters.

Centessa Pharmaceuticals plc is a drug developer that combines ten wholly owned asset-centric subsidiaries, each focused on a single program or biological pathway. Together they develop 16 programs across oncology, hematology, immunology, neuroscience, hepatology, pulmonology and nephrology, many aimed at rare diseases.

Status

IPO

Ticker

CNTA

Exchange

Nasdaq Global Select

Priced

Jun 1, 2021

IPO price

$20.00

Raised

$330M

Market cap at IPO price

$1.75B

First filed

Apr 21, 2021

Underwriters

Morgan Stanley, Goldman Sachs, Jefferies and Evercore ISI

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.